Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a hypertonic saline solution used as a stimulant laxative for bowel cleansing.
## Primary Indications
* Bowel preparation for diagnostic procedures (e.g., colonoscopy) or surgery.
* Relief of occasional constipation.
## Adult Dosing
* **Bowel Preparation:** Typically, one 4.5 oz (133 mL) bottle administered orally or rectally as directed by physician, usually the evening before or morning of the procedure. Some formulations may be 90 mL or 160 mL.
* **Constipation:** One 2.25 oz (66 mL) bottle administered rectally.
## Pediatric Dosing
* **Ages 2-5 years:** 1/2 of the 2.25 oz (66 mL) bottle (approximately 33 mL) rectally.
* **Ages 6-11 years:** One 2.25 oz (66 mL) bottle rectally.
* **Ages 12 years and older:** Same as adult dosing for constipation (one 2.25 oz bottle).
* **Ages younger than 2 years:** Use is generally not recommended due to increased risk of electrolyte imbalance. Consult product labeling or a specialist.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution or avoid in patients with significant renal impairment due to the risk of hyperphosphatemia and hypocalcemia.
* **Cardiac Impairment:** Use with caution in patients with heart failure, as fluid and electrolyte shifts can occur.
## Contraindications
* Congenital or acquired megacolon.
* Intestinal obstruction or perforation.
* Gastrointestinal (GI) bleeding.
* Severe renal impairment.
* Congestive heart failure.
* Acute surgical abdomen.
* Children younger than 2 years of age.
* Patients with ileostomy or colostomy.
* Patients on medication that may affect bowel motility or fluid/electrolyte balance.
## Adverse Effects
* Nausea, vomiting, abdominal cramping, bloating, diarrhea.
* **Serious:** Hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia, metabolic acidosis, dehydration, renal tubular damage, cardiac arrhythmias, seizures.
## Key Drug Interactions
* **Diuretics:** Increased risk of electrolyte imbalances.
* **ACE Inhibitors/ARBs:** Increased risk of hyperkalemia.
* **Calcium Supplements/Vitamin D:** Potential for additive hyperphosphatemia.
* **Medications Affecting GI Motility:** May alter absorption or efficacy.
## Monitoring
* Electrolytes (sodium, potassium, phosphate, calcium) especially in children, elderly, those with renal impairment, or those taking interacting medications.
* Renal function (BUN, creatinine).
* Hydration status.
## Clinical Pearls
* Ensure adequate oral hydration before and after administration.
* Do not administer to patients with symptoms of appendicitis, bowel obstruction, or undiagnosed abdominal pain.
* Administer slowly and retain as long as possible to maximize efficacy.
* Consider alternative bowel preparations for patients with contraindications or significant risk factors.
* Oral sodium phosphate solutions are generally preferred for bowel prep due to better patient tolerability if no contraindications exist.
---
***Disclaimer:** This information is intended for healthcare professionals. Always verify current prescribing information with the official product labeling or a reliable drug information resource before making clinical decisions.*
